Real-world outcomes of advanced melanoma patients not represented in phase III trials

Michiel C. T. van Zeijl, Rawa K. Ismail, Liesbeth C. de Wreede, Alfonsus J. M. van den Eertwegh, Anthonius de Boer, Maaike van Dartel, Doranne L. Hilarius, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Albert J. ten Tije, Astrid A. M. van der Veldt, Gerard Vreugdenhil, John B. A. G. HaanenMichel W. J. M. Wouters*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3461-3470
Number of pages10
JournalInternational Journal of Cancer
Volume147
Issue number12
Early online date4 Jul 2020
DOIs
Publication statusPublished - 15 Dec 2020

Keywords

  • advanced melanoma
  • decision tree
  • ineligibility
  • real-world outcomes
  • survival
  • METASTATIC MELANOMA
  • COMBINED NIVOLUMAB
  • CLINICAL ONCOLOGY
  • AMERICAN SOCIETY
  • SURVIVAL
  • IPILIMUMAB
  • IMMUNOTHERAPY
  • MAGNITUDE
  • THERAPIES
  • BENEFIT

Cite this